In 2009, I wrote that while patient demand for new drugs and devices would increase, the ability of patients and healthcare organizations to pay for such new medicines would decline. This year’s price cuts throughout Europe have now borne this out. Drug firms from Leo Pharma to Novo Nordisk have seen wholesalers stop carrying their new drugs; the reason: cut prices by 25% or don’t get paid … Continue reading at ComplianceZen.com →
From the Blog
Lowering Liability Risks with Supplier Qualification
FDA Compliance Training – Free Consulting?
From the NIH – Biotechnology Landscape 2020
FDA Forecast for 2012
From the PCP Council Science Symposium
Client Success Stories
“Applying the aspects of quality by design you taught us has cut months off our drug development cycles. From determining critical quality attributes at an early stage to streamlining our downstream activities, I continue to see lots of benefits. You gave us an excellent structure to follow.”
- Dr. Thomas Horstmann, Senior Research Director, Boston, Massachusetts
